Quick Answer
KIORA PHARMACEUTICALS INC reported Total Revenue of $0.00 for fiscal year 2025.
KIORA PHARMACEUTICALS INC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $0.00 -100.0% |
$16.02M | $0.00 | — | $0.00 -100.0% |
$12.1K -99.6% |
| Revenue (ASC 606) | — | — | — | — | $0.00 -100.0% |
$12.1K -99.6% |
| Net Income | -$10.84M -401.4% |
$3.59M +128.7% |
-$12.51M +7.9% |
-$13.58M +1.4% |
-$13.77M -70.2% |
-$8.09M -14.0% |
| Diluted EPS | -$2.64 -403.4% |
$0.87 +103.6% |
-$24.25 -30.7% |
-$18.55 +67.5% |
-$57.12 -3127.1% |
-$1.77 |
| Total Assets | $24.25M -33.5% |
$36.48M +166.1% |
$13.71M -26.6% |
$18.68M -7.2% |
$20.13M +32.8% |
$15.16M +49.9% |
| Cash and Equivalents | $8.70M +129.3% |
$3.79M +54.5% |
$2.45M -58.8% |
$5.96M -24.1% |
$7.85M +562.5% |
$1.19M -68.6% |
| Long-Term Debt | — | — | — | — | — | $278.2K |
| Stockholders Equity | $16.13M -37.4% |
$25.76M +321.6% |
$6.11M -46.4% |
$11.41M -21.8% |
$14.58M +49.8% |
$9.73M +46.9% |
| R&D Expense | $10.78M +37.5% |
$7.84M +94.7% |
$4.03M +16.8% |
$3.45M -35.5% |
$5.35M +50.0% |
$3.57M -33.8% |
| Operating Income | -$12.83M -384.5% |
$4.51M +135.8% |
-$12.59M -2.3% |
-$12.31M +13.5% |
-$14.24M -73.3% |
-$8.21M |
| Shares Outstanding | 3.76M -85.9% |
26.74M +3022.6% |
856,182 -20.7% |
1.08M +240.8% |
316,599 -94.3% |
5.56M +36.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $0.00 | — | — |
| Revenue (ASC 606) | September 30, 2020 | $0.00 | — | — |
| Net Income | September 30, 2025 | $26.8K | +100.8% | +101.2% |
| Diluted EPS | September 30, 2025 | $0.01 | +101.2% | +101.9% |
| Total Assets | September 30, 2025 | $29.86M | -22.5% | -6.5% |
| Cash and Equivalents | September 30, 2025 | $5.51M | -2.3% | +435.7% |
| Long-Term Debt | March 31, 2021 | $278.2K | — | +0.0% |
| Stockholders Equity | September 30, 2025 | $22.41M | -25.4% | +1.3% |
| R&D Expense | September 30, 2025 | $2.73M | +24.9% | +5.4% |
| Operating Income | September 30, 2025 | -$794.4K | +77.9% | +66.8% |
| Shares Outstanding | September 30, 2025 | 3.43M | +14.4% | +0.0% |
- KIORA PHARMACEUTICALS INC reported Total Revenue of $0.00 for fiscal year 2025.
- KIORA PHARMACEUTICALS INC showed a decrease of -100.0% in Total Revenue compared to the prior fiscal year.
- KIORA PHARMACEUTICALS INC reported Revenue (ASC 606) of $0.00 for fiscal year 2021.
- KIORA PHARMACEUTICALS INC showed a decrease of -100.0% in Revenue (ASC 606) compared to the prior fiscal year.
- KIORA PHARMACEUTICALS INC reported Net Income of -$10.84 million for fiscal year 2025.
- KIORA PHARMACEUTICALS INC showed a decrease of -401.4% in Net Income compared to the prior fiscal year.
- KIORA PHARMACEUTICALS INC reported Diluted EPS of $2.64 per share (loss) for fiscal year 2025.
- KIORA PHARMACEUTICALS INC showed a decrease of -403.4% in Diluted EPS compared to the prior fiscal year.
- KIORA PHARMACEUTICALS INC reported Total Assets of $24.25 million for fiscal year 2025.
- KIORA PHARMACEUTICALS INC showed a decrease of -33.5% in Total Assets compared to the prior fiscal year.
- KIORA PHARMACEUTICALS INC reported Cash and Equivalents of $8.70 million for fiscal year 2025.
- KIORA PHARMACEUTICALS INC showed an increase of +129.3% in Cash and Equivalents compared to the prior fiscal year.
- KIORA PHARMACEUTICALS INC reported Long-Term Debt of $278.2 thousand for fiscal year 2020.
- KIORA PHARMACEUTICALS INC reported Stockholders Equity of $16.13 million for fiscal year 2025.
- KIORA PHARMACEUTICALS INC showed a decrease of -37.4% in Stockholders Equity compared to the prior fiscal year.
- KIORA PHARMACEUTICALS INC reported R&D Expense of $10.78 million for fiscal year 2025.
- KIORA PHARMACEUTICALS INC showed an increase of +37.5% in R&D Expense compared to the prior fiscal year.
- KIORA PHARMACEUTICALS INC reported Operating Income of -$12.83 million for fiscal year 2025.
- KIORA PHARMACEUTICALS INC showed a decrease of -384.5% in Operating Income compared to the prior fiscal year.
- KIORA PHARMACEUTICALS INC reported Shares Outstanding of 3.76 million shares for fiscal year 2025.
- KIORA PHARMACEUTICALS INC showed an increase of +25.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: